Clinical trials: Basal Ganglia Diseases
Parkinson's Disease
A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
This study is a double-blind, randomized, placebo-controlled, 2-way crossover study to evaluate the safety of CVT-301 levodopa (l-dopa) when co- administered with the first daily dose of oral levodopa/carbidopa for early morning…
- Trial name
- NCT02807675
- Testing
- CVT-301, LIP
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acorda Therapeutics
NSCLC Adenocarcinoma, Solid Tumor
Atamparib in Patients With Advanced Solid Tumors
This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients…
- Trial name
- PARP7 (NCT07374419)
- Testing
- atamparib escalation levels, atamparib RP2D
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Nerviano Medical Sciences (Shanghai) Ltd.
Parkinson Disease
Pivotal Study in Advanced Parkinsons Disease Patients
The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined)…
- Trial name
- NCT00466167
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 76 sites in Austria, Czechia and 12 more
- Volunteers
- 517 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease, Genetic Predisposition
Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.
- Trial name
- NCT04119596
- Testing
- 16S rRNA gene sequencing, DNA-microarray genotyping
- Where
- Russia
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Atlas Biomed
Parkinson's Disease
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with…
- Trial name
- NCT04875962
- Testing
- UCB0599
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Parkinson's Disease
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?
- Trial name
- NCT00957918
- Testing
- nicotine
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Parkinson Disease
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
The Safety, Tolerability, Pharmacokinetic and Food Effect Study of HEC122505MsOH Tablets in Healthy Subjects
- Trial name
- NCT04625361
- Testing
- HEC122505MsOH
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Intracerebral Hemorrhage, Cerebral Hemorrhage
MIECH: The Minimally Invasive Endoscopic Surgery With the Axonpen System for Spontaneous Intracerebral Hemorrhage
The primary objective of this trial is to provide preliminary safety data of minimally invasive endoscopic surgery using the Axonpen™ system for spontaneous intracerebral hemorrhage (ICH).
- Conditions
- Intracerebral Hemorrhage, Cerebral Hemorrhage, Intracranial Hemorrhage, Basal Ganglia Hemorrhage
- Trial name
- NCT04839770
- Testing
- Axonpen system
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Clearmind Biomedical Inc.
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls
This is an experimental medicine study to evaluate the kinetics of cerebrospinal fluid (CSF) biomarkers in subjects with Alzheimer's disease (AD) or progressive supranuclear palsy (PSP) compared to healthy controls using a heavy…
- Trial name
- NCT01348061
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- KineMed
Parkinson's Disease
ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease
The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRgFUS) treatment of patients with L-dopa induced dyskinesia of Parkinson's disease (LID PD).
- Trial name
- NCT02347254
- Testing
- Transcranial ExAblate
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- InSightec
Parkinson's Disease
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage
- Trial name
- NCT02906488
- Where
- 127 sites in Japan
- Volunteers
- 839 people
- Sponsor
- AbbVie
Parkinson's Disease
Kinesia HomeView - Home Diary Comparison
The objective is to compare the sensitivity and test-retest reliability of Kinesia HomeView to electronic and hand-written diaries for tracking medication state in the home.
- Trial name
- NCT01920425
- Testing
- Kinesia HomeView, Hand-written diary
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease
This is multicentre, proof of concept, randomized, double-blind, parallel-group, placebo-control study in 40 Parkinson's Disease (PD) patients.
- Trial name
- CUREPARK (NCT03899324)
- Testing
- Bumetanide white, oblong, scored tablet
- Where
- France
- Volunteers
- 40 people
- Sponsor
- B&A Therapeutics
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Huntington's Disease
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
- Trial name
- NCT05107128
- Testing
- SAGE-718
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 189 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a…
- Trial name
- NCT00642889
- Testing
- Safinamide
- Volunteers
- 227 people
- Sponsor
- Newron Pharmaceuticals SPA
Huntington Disease
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
This is an open label, dose escalation clinic trial of ER2001 intravenous injection to evaluate safety, tolerability and pharmacokinetics of ascending single and multiple doses of intravenously administered ER2001 in patients…
- Trial name
- NCT06024265
- Testing
- ER2001 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- ExoRNA Bioscience
Parkinson's Disease
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
The primary objective of the study is to evaluate the safety and tolerability of ADX48621 in Parkinson's disease patients following four weeks of dosing.
- Trial name
- NCT01336088
- Testing
- ADX48621
- Where
- 25 sites in United States, Austria and 2 more
- Volunteers
- 83 people
- Sponsor
- Addex Pharma S.A.
Parkinson's Disease
Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.
- Trial name
- NCT00346827
- Testing
- Apomorphine Nasal Powder
- Volunteers
- 36 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.